Since the launch of rh-insulin is some years away, as are the key clinical trials, it brings investors back to watching what's happening in Biocon's existing business and the next earnings' release
Since the launch of rh-insulin is some years away, as are the key clinical trials, it brings investors back to watching what's happening in Biocon's existing business and the next earnings' release
Share this Article
Recommended